Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citalopram + zinc sulfate is a non-standardized combination of two agents: citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and zinc sulfate, an inorganic salt used as a dietary supplement to provide elemental zinc. Citalopram acts by inhibiting the reuptake of serotonin in the central nervous system, thereby increasing serotonergic activity and improving symptoms of depression[5][6]. Zinc is an essential trace element involved in numerous enzymatic processes and has been studied for its potential role in modulating mood and supporting antidepressant efficacy. Clinical studies suggest that adjunctive zinc supplementation with SSRIs like citalopram may enhance reduction of depressive symptoms compared to SSRI therapy alone[3]. This combination does not represent a commercially available fixed-dose product but may be used off-label or as part of clinical research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citalopram + zinc sulfate.